The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies (PADs). by Jandus, Peter et al.
American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
editorial@hematology.org
The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies (PADs)
Tracking no: BLD-2019-001705R1-FINALFILES
Peter Jandus (University Hospital of Geneva, Switzerland) Kayluz Frias Boligan (University of Bern, ) David Smith (Emory University School of
Medicine, United States) Elisabeth de Graauw (University of Bern, Switzerland) Bodo Grimbacher (Satellite Center Freiburg, Germany) Camilla
Jandus (University of Bern, Switzerland) Mai Abdelhafez (Modern Science and Art University (MSA), Egypt) Alain Despont (University of Bern,
Switzerland) Nicolai Bovin (Auckland University of Technology, New Zealand) Dagmar Simon (Inselspital, Switzerland) Robert Rieben (University
of Bern, Switzerland) Hans-Uwe Simon (University of Bern, Switzerland) Richard Cummings (Harvard Medical School, United States) Stephan
von Gunten (Institute of Pharmacology, University of Bern, Switzerland) 
Abstract:
Immune system failure in primary antibody deficiencies (PADs) has been linked to recurrent infections, autoimmunity and cancer, yet clinical
judgment is often based on the reactivity to a restricted panel of antigens. Previously, we demonstrated that the human repertoire of
carbohydrate-specific IgG exhibits modular organization related to glycan epitope structure. The current study compares the glycan-specific IgG
repertoires among different PAD entities. Distinct repertoire profiles with extensive qualitative glycan-recognition defects were observed,
characterized by the common loss of Gala- and GalNAc-reactivity and disease-specific recognition of microbial, self-antigens and tumor-
associated carbohydrate antigens. Antibody repertoire analysis may provide a useful tool to elucidate the dimension and clinical implications of
the immune system failure in individual patients.
Conflict of interest: No COI declared
COI notes: 
Preprint server: No; 
Author contributions and disclosures: S.V.G. and P.J. designed the study. K.F.B., P.J. and S.V.G. wrote the manuscript. K.F.B. and
S.V.G. analyzed the data. Glycan array experiments at the CFG were conducted under supervision of D.F.S. and R.D.C. Database searches
and computational analysis of the data set was performed by K.F.B. Patient sample collection, classification and preparation were done by B.
G., C.J. and P.J. Experimental work was done by K.F.B., E.D.G., M.A., A.D. under supervision by D.S., H.U.S., R.R. and S.V.G. Glycan
synthesis was supervised by N.B. All authors had full access to the data, helped draft the report or critically revised the draft, contributed to
data interpretation, reviewed and approved the final version of the report.
Non-author contributions and disclosures: No; 
Agreement to Share Publication-Related Data and Data Sharing Statement: emails to the corresponding author
Clinical trial registration information (if any): 
 Blood First Edition Paper, prepublished online September 19, 2019; DOI 10.1182/blood.2019001705
 Copyright © 2019 American Society of Hematology
For personal use only. on October 7, 2019. at Universitaetsbibliothek Bern www.bloodjournal.orgFrom 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
3
7
5
5
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
The architecture of the IgG anti-carbohydrate repertoire in primary antibody 1 
deficiencies (PADs) 2 
Running tittle: Carbohydrate-specific IgG repertoire in PAD 3 
Author list: Peter Jandus1†, Kayluz Frias Boligan2†, David F. Smith3, Elisabeth de 4 
Graauw2, Bodo Grimbacher4-7, Camilla Jandus2,8,9, Mai M. Abdelhafez10, Alain 5 
Despont10, Nicolai Bovin11,12, Dagmar Simon13, Robert Rieben10, Hans-Uwe 6 
Simon2,14, Richard D. Cummings3, 15, Stephan von Gunten2 7 
1
Division of Clinical Immunology and Allergy, Department of Internal Medicine, University Hospital and Faculty of 8 
Medicine, Geneva, Switzerland 9 
2
Institute of Pharmacology, University of Bern, Bern, Switzerland 10 
3
Emory Comprehensive Glycomics Core, Department of Biochemistry, Emory University School of Medicine, 11 
Atlanta, GA, USA 12 
4
Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, 13 
Albert-Ludwigs-University of Freiburg, Germany 14 
5
DZIF – German Center for Infection Research, Satellite Center Freiburg, Germany 15 
6
CIBSS – Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany 16 
7
RESIST – Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Germany 17 
8
Translational cytokine secreting lymphocyte group, Department of Oncology UNIL CHUV, University of 18 
Lausanne, Lausanne, Switzerland 19 
9
Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland 20 
10
Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland 21 
11
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science, Moscow, Russian 22 
Federation 23 
12
Auckland University of Technology, Auckland, New Zealand 24 
13
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 25 
14
Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia. 26 
15
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 27 
Massachusetts, USA 28 
 29 
  30 
For personal use only. on October 7, 2019. at Universitaetsbibliothek Bern www.bloodjournal.orgFrom 
Corresponding author: Stephan von Gunten, University of Bern, 3012 Bern, 31 
Switzerland. Phone: 41-31-632-32-98; Fax: 41-31-632-49-94. E-mail: 32 
stephan.vongunten@pki.unibe.ch 33 
 34 
 35 
KEY WORDS: Primary immunodeficiency diseases (PID), primary antibody 36 
deficiencies (PAD), common variable immunodeficiency disorders (CVID), glycan 37 
array, xenotransplantation 38 
Article length: 3’818 words  39 
For personal use only. on October 7, 2019. at Universitaetsbibliothek Bern www.bloodjournal.orgFrom 
KEY POINTS: Repertoire analysis by microarray technology constitutes a powerful 40 
tool to evaluate immune system failure in PADs. 41 
 42 
 43 
ABSTRACT 44 
Immune system failure in primary antibody deficiencies (PADs) has been linked to 45 
recurrent infections, autoimmunity and cancer, yet clinical judgment is often based on 46 
the reactivity to a restricted panel of antigens. Previously, we demonstrated that the 47 
human repertoire of carbohydrate-specific IgG exhibits modular organization related 48 
to glycan epitope structure. The current study compares the glycan-specific IgG 49 
repertoires among different PAD entities. Distinct repertoire profiles with extensive 50 
qualitative glycan-recognition defects were observed, characterized by the common 51 
loss of Gal- and GalNAc-reactivity and disease-specific recognition of microbial, 52 
self-antigens and tumor-associated carbohydrate antigens. Antibody repertoire 53 
analysis may provide a useful tool to elucidate the dimension and clinical implications 54 
of the immune system failure in individual patients. 55 
 56 
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INTRODUCTION 64 
 Inadequate humoral responses to carbohydrate-structures represent a 65 
common feature of primary antibody deficiencies (PADs), despite the pathogenetic 66 
heterogeneity of these disorders, involving monogenetic, polygenetic and still 67 
unexplained defects1,2. These disorders are associated with a plethora of clinical 68 
sequelae including severe and recurrent infections, microbial dysbiosis, 69 
autoimmunity, allergy, granulomatous disease and malignancy1,3,4. 70 
The surface of all living cells is glycosylated, whereby the composition varies 71 
between cell type5, individuals, or species6. The prominent exposure of carbohydrate-72 
structures (glycans) on the surface of cells or bacterial capsules, renders them 73 
accessible to antibodies, which facilitates the detection and elimination of pathogens 74 
or aberrant cells, but also leads to adverse reaction in transfusion/transplantation 75 
procedures (blood groups antigens), or to the acute rejection of xenografts (e.g. Gal-76 
 structures). Due to altered expression of biosynthetic enzymes, such as 77 
glycosyltransferases or glycosidases, the glycome of cells is often changed under 78 
pathological conditions, including cancer7. While tumor-associated carbohydrates 79 
(TACAs) are exploited as diagnostic markers8, there is also evidence for naturally-80 
occurring antibodies to TACAs in healthy individuals9. 81 
Insufficient responses to glycan-based vaccines or low titers of 82 
isohemagglutinins, antibodies to polysaccharide blood group antigens, are 83 
characteristic and diagnostic features of common variable immunodeficiency (CVID), 84 
the most frequent symptomatic antibody deficiency diagnosed in adulthood10,11. 85 
Patients with specific antibody deficiency (SPAD) exhibit poor responses to structural 86 
or capsular polysaccharides of bacteria (e.g. S. pneumoniae, H. influenzae), despite 87 
the presence of normal serum concentrations of IgG, IgM and IgA12. Antibodies from 88 
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different IgG subclasses are known to contain different specificities for glycan-89 
structures9,13, which may explain the predisposition of certain patients with IgG 90 
subclass deficiency (IgGSD) to infections with encapsulated bacteria12. However, 91 
current knowledge on the failure to raise adequate levels of glycan-specific 92 
antibodies in PAD is mainly based on experience with specific bacterial antigens. 93 
The clinical assessment of PADs by diagnostic vaccination (e.g. 94 
pneumococcal vaccines, S. typhi Vi vaccine14) or the measurement of pre-existing 95 
antibody titers (e.g. isohemagglutinins) relies on a restricted number of glycan 96 
epitopes, thus providing only a narrow perspective of the actual dimensions of the 97 
immunodeficiency. Further disadvantages of diagnostic vaccination include 98 
diagnostic delay, laboratory-to-laboratory variation, serotype-specific responses, age 99 
differences in antibody responses, or the challenging interpretation of 100 
pre-immunization versus post-immunization specific antibody levels in patients not 101 
receiving IgG replacement therapy10,11,15-18. The broader assessment of glycan-102 
specific antibodies in patients may better reflect the immune defect and also facilitate 103 
treatment decisions, such as regarding life-long IgG replacement therapy. 104 
Glycan array technology allows the high-throughput analysis of specific 105 
antibody responses to carbohydrate antigens19-21. In a previous study using glycan 106 
array version 5.1 of The Consortium for Functional Glycomics (CFG) to decipher the 107 
IgG repertoire of healthy individuals we found that classes of glycans were 108 
recognized with different intensity, depending on the terminal carbohydrate-moiety9. 109 
Here, we employed glycan array technology to investigate the IgG antibody repertoire 110 
of PAD patients in terms of clinically relevant carbohydrate epitopes, including 111 
microbial glycans, self- or xenoantigens, and TACAs.   112 
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MATERIALS AND METHODS 113 
Study design  114 
This non-randomized study was designed to investigate the human IgG anti-115 
carbohydrate repertoire, in healthy and disease conditions, using glycan array 116 
technology combined with a computational system level approach. To this end, sera 117 
or purified IgG from healthy individuals or patients, as well as control antibodies were 118 
screened on microarrays by the Consortium for Functional Glycomics (CFG) or the 119 
US National Center for Functional Glycomics (NCFG). 120 
Patient samples 121 
Human blood was collected from healthy individuals (HD) or patients upon informed 122 
and written consent in accordance with the Declaration of Helsinki. All experimental 123 
protocols were approved by the local institutional and/or licensing committees (KEK-124 
BE: 148/10 and KEK No. 224/01). Therapeutic naïve patients followed at the 125 
University Hospital of Bern from January 2005 to December 2011 were 126 
retrospectively identified. Additional sera of therapeutic naïve patients without IgG 127 
replacement therapy were provided from B.G. CVID was defined in accordance with 128 
the criteria of the Pan-American Group for Immunodeficiency and the European 129 
Society for Immunodeficiency22. Inclusion criteria for IgGSD were a normal total IgG 130 
concentration with a significant decrease (more than two standard deviations below 131 
the mean for the age) in the serum concentrations of one or more IgG subclasses23 132 
with recurrent episodes of infection. Symptomatic hypogammaglobulinemia (HGG) 133 
was defined with decreased total IgG concentration, but not fulfilling criteria for CVID 134 
with respect to a reduction of two immunoglobulin isotypes and/or reduced response 135 
to vaccination. For diagnostic vaccination the pneumococcal polysaccharide vaccine 136 
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(PPV) Pneumovax-23 (MSD, Lucerne, Switzerland) was used in patients with IgG 137 
levels at or higher than 4 g/L. Levels of pneumococcal capsular polysaccharide 138 
(PCP) IgG > 50 mg/L and for PCP IgG2 > 40 mg/L were considered as normal. A 139 
sufficient PPV vaccination response was defined as PCP titers above these levels 140 
and/or PCP IgG and IgG2 levels above 100 mg/L and/or a 4-fold increase of post-141 
vaccination PCP IgG and PCP IgG2 titers as detected 4 to 6 weeks after vaccination. 142 
SPAD was diagnosed in patients with normal total immunoglobulin and IgG subclass 143 
concentrations but impaired pneumococcal polysaccharide vaccine (PPV) response. 144 
The characteristics of the different groups are summarized in Table S1. Patients were 145 
not stratified for specific infections. The sera from these patients were individually 146 
screened in the NCFGv2 glycan array or pooled in the indicated groups and 147 
screened in the CFG glycan array. IgG purification was performed by affinity 148 
chromatography in Ab SpinTrap columns (GE Healthcare). Pooled sera from patients 149 
and healthy donors were directly applied to the columns and the purification 150 
procedures performed according to manufacturer instructions. The control IgG 151 
preparation (IgG control mix) was prepared by mixing two monoclonal human 152 
myeloma proteins, IgG1 (67%) and IgG2 (33%), purchased from Sigma-Aldrich. 153 
This process resulted in a / ratio of 0.5, which is well within the range found in 154 
normal serum (0.26 to 1.65). The concentration of IgG in the different samples was 155 
determined using a Behring Turbitimer instrument (Dade Behring). The quality of the 156 
isolated antibodies was checked by SDS-PAGE under reducing and non-reducing 157 
conditions (Figure S1). 158 
Glycan array analysis 159 
The glycan microarrays from the CFG 160 
(http://www.functionalglycomics.org/static/consortium/resources/resourcecoreh8.shtm161 
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l) were prepared from amine functionalized glycan structures covalently coupled in 162 
microarrays to N-hydroxysuccinimide-derivatized microscope slides as previously 163 
described24. On NCFG array version 2 (NCFGv2) carbohydrates were conjugated 164 
with the fluorescent linker AEAB, by reductive amination with sodium 165 
cyanoborohydrate to form glycan-AEABs (GAEABs). For both arrays, the human sera 166 
or purified IgG or IgG control mix, were identically processed and screened at 167 
180g/ml using a secondary biotinylated anti-human IgG mAb (clone HP-6043) at 5 168 
μg/ml followed by Alexa633-coupled streptavidin9. A positive streptavidin control was 169 
used. Sample preparation and analysis was performed as indicated on the CFG 170 
website (www.functionalglycomics.org). To determine the specific binding to selected 171 
glycans, the antibody binding ratio (ABR) was calculated. The computed ABR 172 
represents the quotient of the respective sample relative fluorescent units (RFU) and 173 
the corresponding IgG control mix RFU. Data are expressed as the mean of RFU or 174 
ABR values from six repeated experiments, if not indicated otherwise. 175 
Database search 176 
The identity or characteristics of glycans was investigated by consulting the 177 
databases of the Consortium of Functional Glycomics 178 
(http://www.functionalglycomics.org/fg/) or PubMed 179 
(http://www.ncbi.nlm.nih.gov/pubmed/guide/). The online Bacterial Carbohydrate 180 
Structure Data Base (BCSDB) was consulted to identify the bacterial origin of the 181 
glycans (http://csdb.glycoscience.ru/bacterial/). 182 
Statistical analysis 183 
Correlation matrixes, heatmaps and hierarchical clustering were performed using “R” 184 
(The R Foundation for Statistical Computing, Version 3.0.2)25. Representation of the 185 
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data was done using the function heatmap.2 from the package gplots26. Hierarchical 186 
clustering and dendrograms were calculated with the complete method of the hclust 187 
function. Statistical analysis and other illustrations were performed using Microsoft 188 
Excel (Microsoft Corporation, 2011, Version 14.0.0) and GraphPad PRISM 189 
(Graphpad Software, Inc., Version 6.0c). For clique distribution analysis, only groups 190 
with common terminal carbohydrate moiety that are represented at least with 12 191 
glycans (2% of total) on CFG glycan array version 5.1 were taken into consideration. 192 
For statistical analysis, Kruskal-Wallis, Student’s t-test, Spearman correlation and 193 
Two-way ANOVA tests were used. Given the small size of the group (n=2), the CVID 194 
PPVlow subset on the NCFGv2 array was excluded when group comparisons were 195 
performed.  196 
 197 
Further methods are available in the supplemental data, available on the Blood Web 198 
site. 199 
For original data, please contact the corresponding author. 200 
  201 
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RESULTS 202 
Broad carbohydrate reactivity defects (CRD) in diverse PAD entities 203 
Sera from PAD patients or healthy donors (HD) were screened on CFG glycan array 204 
version 5.1 to analyze the IgG binding reactivity to 610 distinct glycans at 180g/ml. 205 
In accordance with previous reports9,13 this assay concentration was determined to 206 
be optimal, resulting in reproducible IgG glycan-binding patterns with minimal 207 
background. Cohorts included patients with symptomatic hypogammaglobulinemia 208 
(HGG n=76), SPAD (n=5) or IgG subclass deficiency (IgGSD; n=8), CVID (n=25), 209 
CVID with low PPV vaccination response (CVID PPVlow; n=6) or HD (n=43). 210 
Using this platform, we observed broad IgG reactivity to printed glycans in 211 
pooled sera from healthy donors (Fig. 1A; Table S2), which is consistent with 212 
previously published data9,13,21,27-29. In contrast, marked reduction of overall glycan 213 
binding intensities was observed for all investigated PAD patient subsets, with lowest 214 
averaged relative fluorescence units (RFU) in CVID, particularly in CVID PPVlow 215 
patients (Fig. 1A). Next, IgG was purified from CVID, HGG and healthy donor sera by 216 
affinity chromatography, and then screened on glycan array. As with whole sera, anti-217 
glycan reactivity of equimolar, purified IgG from immunocompromised patients 218 
presented lower RFU values on average compared to healthy controls (Fig. S1). 219 
In an effort to compare the carbohydrate-specific IgG repertoires between 220 
PAD patients and healthy subjects, individual sera were screened. To this end glycan 221 
array version 2 from the US National Center of Functional Glycomics (NCFGv2) 222 
containing 147 glycans was used, which allowed us to include more samples. 223 
Identical glycans were similarly recognized on both arrays (Fig. S2). Figure 1B 224 
illustrates the computed reactivity matrix (mean RFU values) ordered by a 225 
dendrogram clustering algorithm30. Columns represent the antibody reactivity profiles 226 
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(reactivity of each specific glycan for the different sera samples), and the rows reflect 227 
the immune profiles for each patient subgroup. The dendrogrammed reactivity matrix 228 
illustrates the broader spectrum of glycan reactivity in healthy donor sera compared 229 
to all screened PAD patient subgroups, yet revealing a similar binding profile as 230 
compared to the SPAD cohort. The glycan-binding profiles of IgGSD, HGG and CVID 231 
sera displayed a narrower spectrum of glycan reactivity, which was most impaired in 232 
the CVID subgroup. CVID and CVID PPVlow patients also exhibited the lowest 233 
averaged RFU values (Fig. S2). No clear clustering of individual immunoprofiles was 234 
observed for total glycans, which was expected as the arrays contain synthetic 235 
glycans without known biological relevance (Fig. S2). 236 
Glycan-specific IgG antibodies to bacterial antigens in PAD 237 
PADs are characterized by recurrent, severe or unusual bacterial infections, 238 
especially by bacteria protected by a polysaccharide capsule. Thus, we decided to 239 
analyze the IgG reactivity profiles to known bacterial carbohydrates. On glycan array 240 
CFG version 5.1, we previously identified 121 bacterial carbohydrate antigens 241 
consulting the Bacterial Carbohydrate Structure Data Base (BCSDB)9, providing a 242 
platform for high-throughput analysis for antibody reactivity to carbohydrate epitopes 243 
of multiple bacterial species. The printed glycans include capsular and structural 244 
oligosaccharides, as well as exopolysaccharides of commensal and pathogenic 245 
bacterial species9. In comparison to immunoprofiles of healthy subjects, Spearman's 246 
rank correlation analysis revealed divergent IgG reactivity profiles to bacterial glycan 247 
epitopes in PAD cohorts, with the lowest correlation of 0.34 CVID PPVlow patients and 248 
0.57 for CVID, when pooled sera were screened on the CFG array (Fig. 2A). Figure 249 
2B illustrates the collective reactivity matrix (mean RFU values) of individual sera to 250 
65 bacterial glycans on the NCFGv2 array. Hierarchical clustering analysis revealed 251 
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a substantial loss of reactivity for the IgGSD, HGG and CVID cohorts. An extensive 252 
reduction of anti-bacterial reactivity was also found for recognition of the majority of 253 
121 bacterial glycans on the CFG array version 5.1 in pooled sera from patients in 254 
these cohorts (Fig. S3). No clear clustering of individual immunoprofiles was 255 
observed for bacterial glycans, which may be due to differential natural exposure to 256 
bacteria (Fig. S3). 257 
The glycan array technology combined with the consultation of the BCSDB 258 
databank allowed to screen in parallel several distinct epitopes that were identified as 259 
glycan constituents of specific bacteria. Figure 2C shows individual profiles of IgG 260 
reactivity to glycans on the NCFGv2 array that are found in E. coli (glycans: n=15), H. 261 
pylori (n=15), N. meningitidis (n=6), H. influenzae (n=3), S. pneumoniae (n=2), and 262 
Salmonella (n=2) species. Heterogenous immunoprofiles were observed in all 263 
cohorts, including healthy individuals. However, reactivity profiles were particularly 264 
low in CVID and CVID PPVlow, who exhibited a significant loss of IgG antibodies 265 
specific for pathogens and commensals, including antigens to which human beings 266 
are frequently exposed and immunized. Missing antibodies against Neisseria 267 
meningitis and Salmonella in the different groups may reflect lack of exposure to 268 
these pathogens. 269 
Recognition of TACA and Siglec ligands in PAD 270 
One life-threatening complication of PAD, in particular of CVID, is the 271 
occurrence of malignancies1,31-34. Since altered surface glycosylation is a hallmark of 272 
cancer and influences different aspects of tumor progression and anti-tumor 273 
immunity7,35,36, we set out to explore IgG reactivity to tumor-associated carbohydrate 274 
antigens. Figure 3A demonstrates the IgG reactivity profiles to twenty-two glycan 275 
epitopes on CFG glycan array version 5.1 that constitute well-established TACAs. In 276 
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accordance with our previous data9, healthy donor sera contained natural antibodies 277 
against TACAs. High reactivity was found against Lewis antigen-related TACAs, 278 
gangliosides, Thomsen-Friedenreich (TF) and globo-series-associated antigens. 279 
Loss of anti-TACA IgG reactivity was found in all examined PAD patient subgroups. 280 
The reduced binding activity by IgG was most dominant in CVID PPVlow donors, 281 
followed by CVID patients, as computed based on RFU profiles and represented as 282 
circular dendrogram (Fig. 3B). To further explore these findings we analyzed anti-283 
TACA signatures of individual sera screened on the NCFGv2 array. Most sera from 284 
healthy individuals exhibited high anti–TACA reactivity to Forssman antigen, 285 
Globoside, Globo H and SSEA-4 hexaose, but heterogenous binding to other TACAs 286 
(Fig. 3C). The substantial loss of anti-TACA reactivity in CVID was confirmed in 287 
individual sera. In contrast, antibody binding to the Forssman antigen was found in all 288 
cohorts and all screened individual sera (Fig. 3A and C), indicating that this glycan-289 
epitope is highly immunogenic with widely maintained specific antibody production in 290 
the PAD patients. Indeed, in the CVID PPVlow and some CVID patients, Forssman 291 
antigen was the only investigated TACA for which higher intensity signals were 292 
detected. Reactivity to GM1 was particularly low in CVID patients. This is remarkable 293 
as GM1 expression is present and positively correlates with rituximab treatment 294 
response in non-Hodgkin’s lymphoma37, which is among the most frequent 295 
malignancies occurring in these patients10. 296 
Overexpression of sialylated TACAs frequently occurs in tumors and 297 
hypersialylation has been linked to tumor progression and immune escape by the 298 
engagement of inhibitory Siglec receptors on leukocytes7,36,38-40. In PAD cohorts the 299 
antibody recognition of certain sialoglycans with known Siglec binding capacity was 300 
similar or reduced on the glycan array compared to healthy donor responses (Fig. 301 
S4). However, for two ligands of CD22/Siglec-2, expressed on B cells, binding was 302 
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high (# 377) or even increased (# 268). Little is known about the tissue expression of 303 
these two ligands and it remains to be shown if such antibodies at higher levels might 304 
interfere with the CD22 receptor / ligand axis to unleash B cell responses under 305 
certain circumstances. 306 
Failure to raise Gal- and GalNAc-directed IgG antibodies in PAD 307 
The composition of glycan antigens, in particular the terminal carbohydrate-308 
moiety, has been linked to the immunogenicity of a given glycan in healthy 309 
individuals9. This raised the question about the effect of the relationship between 310 
immune system failure (ISF) in PAD subgroups and the structure-related 311 
immunogenicity on the architecture of the glycan-specific IgG repertoire. A binary 312 
deviation matrix was computed considering statistical deviation (P < 0.05) of IgG 313 
binding (RFU values) for each PAD cohort and each glycan compared to healthy 314 
donor data and reordered by a dendrogram clustering algorithm (Fig. 4A). The rows 315 
in this matrix indicate the binary antibody reactivity profiles, and the columns 316 
represent the deviation immune profiles for each PAD subgroup. By hierarchical 317 
clustering analysis four major subgroups were identified: predominant were clique 4 318 
representing glycans with deviation in all PAD cohorts (n=293; 48%) and clique 2 319 
containing glycans without deviation in all PAD cohorts (n=245; 40%); of lower 320 
magnitude were clique 1 (n=5; 1%) and clique 3 (n=67; 11%) encompassing glycans 321 
with heterogeneous IgG binding activities between subgroups (Table S3). 322 
 Given the association between immunogenicity and terminal carbohydrate 323 
moiety of glycans9,41, the clique distribution of glycans was investigated based on 324 
their structure. The most dominant deviation was found for Gal- and GalNAc-325 
terminated glycans (Fig. 4B). Forty-seven (85.5%) versus only one (1.8%) Gal-326 
structure(s), and 37 (68.5%) versus 12 (22.2%) GalNAc-terminated glycans were 327 
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represented in clique 4 or clique 2, respectively. In accordance, the IgG antibody-328 
binding levels (RFU values) of Gal- and GalNAc-terminated glycans were lower in 329 
all cohorts (Fig. 4C, D). In depth analysis computing a deviation matrix based on P 330 
values and hierarchical clustering analysis revealed large glycan clusters that were 331 
concomitantly either non-aberrant (clique B) or aberrant (clique E) for all disease 332 
entities compared to healthy individuals (Fig. 4E), whereby Gal- (70.9%) and 333 
GalNAc- (62.9%) terminated glycans were most prevalent in clique E (Fig. 4F), 334 
indicating failed antibody responses to these specific structures. 335 
As a consequence of the inactivation of the GGTA1 gene encoding for 336 
1,3galactosyltransferase (GalT), humans, apes and Old World monkeys do not 337 
express the Galili epitope Galα1-3Galβ1-4GlcNAcβ39. Natural antibodies to this 338 
xenoantigen in most humans, eventually generated in response to the microbiota of 339 
the host, are considered a key factor in the rejection of xenografts43, and 340 
necessitated the development of GalT knockout (GalTKO) animals44,45. Using a 341 
suspension array, we examined individual sera from patients (HGG, n=37; CVID, 342 
n=15; IgGSD, n=8) and healthy donors (n=18) for IgG reactivity to the Galili epitope 343 
and other Gal- and GalNAc-terminated structures including, LN (Galα1-344 
4GlcNAcβ), A3GN (Galα1-3GlcNAcβ), or A and B blood group antigens (Fig. 5A 345 
and S5). Low isohemagglutinins are frequently observed in CVID patients11. 346 
Consistent with this observation, we found reduced IgG reactivity to blood group A 347 
and B antigens also in the HGG, SPAD and IgGSD cohorts (Fig. S6). The IgG 348 
reactivity to Gal- and GalNAc-terminated epitopes was consistently lower in most 349 
PAD patients, whereby the reduction was most significant for the Galili epitope, as 350 
evidenced by statistical analysis (Fig. 5A and S5). 351 
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Given the significant loss of anti-Galili reactivity in PAD patients, functional 352 
implications were tested in a xenoreactivity assay, analyzing antibody-dependent cell 353 
cytotoxicity (ADCC) of primary human natural killer (NK) cells directed against the 354 
porcine kidney cell line PK15. On this cell line the Galili epitope is highly expressed 355 
on the surface and lost following enzymatic digestion by -galactosidase as 356 
assessed by flow cytometry (Fig. 5B). Sera from healthy donors induced substantial 357 
NK cell-mediated ADCC activity against the Galili-positive PK15 cells, which was 358 
abolished following -galactosidase treatment of the porcine target cells (Fig. 5C), 359 
illustrating the dependence of the xenogeneic activity on Gal- epitopes, including 360 
Galili. In contrast, CVID sera failed to promote NK cell-mediated ADCC against the 361 
porcine Galili-positive target cells at equimolar IgG concentrations (1mg/mL), 362 
indicating a repertoire defect for the recognition of xenogeneic antigens. Moreover, 363 
the loss of the xenogeneic potential of CVID sera was demonstrated in a modified 364 
version of an established model for antibody-mediated skin damage46,47, involving 365 
cryosections of porcine skin incubated with patients' sera and leukocytes from 366 
healthy donors and the assessment of dermal-epidermal separation. Porcine skin 367 
damage was significantly lower in the presence of CVID sera compared to human 368 
control sera at equimolar IgG concentrations (Fig. 5D). Together, these data provide 369 
evidence for humoral immune system failure beyond quantitative antibody deficiency, 370 
which involves repertoire defects in PAD. 371 
  372 
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DISCUSSION 373 
The emerging picture is that the human IgG anti-carbohydrate repertoires in 374 
health9, and in primary antibody deficiencies, exhibit a modular organization, yet with 375 
a different architecture in PAD. Translated to Cohen’s concept of immune 376 
computation48, our data imply that primary antibody deficiency is not solely 377 
characterized by aberrant antibody production, but features disturbed immune-378 
system response states (the output) due to an altered algorithm to compute 379 
immunogenic states (the input) that is dictated by impaired cellular and molecular 380 
networks of innate and adaptive immunity49,50. 381 
Despite the heterogeneous genetic basis across PAD entities1, deviation 382 
mapping revealed significant repertoire similarities pointing toward a common 383 
disease-modifying algorithm that drives humoral immune system failure. Dominant 384 
was the reduced or lost specificity for Galor GalNAc-terminated glycan epitopes in 385 
PAD patients, for which healthy individuals express high levels of naturally occurring 386 
antibodies, eventually in response to immune stimulation by carbohydrate antigens of 387 
their microbiota9,41. The loss of Galor GalNAc-specific antibodies might thus 388 
reflect the lost capacity to induce these antibodies in response to the host microbiota, 389 
or reflect the microbial dysbiosis in PAD4, or both. Interestingly, bacteria and tumor 390 
cells use certain glycosylation patterns to escape immunity, such as sialoglycans that 391 
engage inhibitory Siglec receptors on leukocyte subsets of myeloid and lymphoid 392 
lineages6,35,39,40,51. It remains to be shown if naturally-occurring antibodies to TACA 393 
are also induced by the microbiota and if the observed loss has consequences for 394 
PAD patients. Notably, the loss of IgG reactivity to tumor antigens was most evident 395 
in the CVID cohort, a disorder in which the incidence of malignancy is increased10, 396 
supporting the concept of aberrant immune surveillance in PID52. For instance, we 397 
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observed low antibody reactivity to TACAs known to be expressed on CVID-398 
associated malignancies, such as GM1 in non-Hodgkin’s lymphoma37, or Thomson-399 
Friedenreich antigen in gastric cancer53,54. However, tumor glycosylation patterns and 400 
their immunoreactivity remain to be fully explored for CVID-associated malignancies. 401 
Glycoimmunology remains a relatively underdeveloped field and the need for 402 
interdisciplinary collaborations and the enhanced training of glycoscientists in 403 
biomedical areas has been identified55. In line with this, there is also a demand for 404 
tools, such as glycan arrays, the development of which is challenging given the 405 
availability of differently synthesized or purified glycans. However, this initial study 406 
highlights the potential and the need to expand glycan array studies in PAD using 407 
biological samples from larger patient cohorts. Clusters of glycans were identified 408 
with different reactivity profiles between PAD subgroups (cliques 3, A, C, D), which 409 
may be candidates for diagnostic use. In future studies, it will also be advisable to 410 
compare glycan-specific antibody profiles with clinical and laboratory parameters 411 
(e.g. switched memory B cell numbers, blood groups), and in specifically classified 412 
patient subsets56. 413 
The broad and qualitative assessment of the immune system failure (ISF) in 414 
individual patients may be informative regarding the severity of the disease, 415 
eventually leading to more personalized treatment decisions. Glycan array 416 
technology may thus provide a useful option for the individual assessment of ISF and 417 
facilitate clinical practice, especially given the heterogeneity of PAD entities with a 418 
growing list of identified pathogenetic defects2. However, our broad analysis 419 
demonstrates the extent of the skewed IgG repertoire with impaired reactivity to 420 
biologically relevant glycan epitopes, including those linked to PAD-associated 421 
clinical manifestations, such as infection, malignancy and autoimmunity1,10. Our 422 
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systems immunology approach highlights the power of high-throughput assessment 423 
of humoral immune system failure by microarray technology, which may have 424 
potential ramifications for the diagnosis, classification and therapy of PAD patients. 425 
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FIGURE LEGENDS 609 
Figure 1. Antibody repertoire profiling on CFG and NCFGv2 glycan arrays 610 
reveals broad carbohydrate recognition defects in symptomatic primary 611 
antibody deficiencies (PADs). (A) Glycan-specific binding of serum IgG screened 612 
at 180 g/ml on CFG glycan array version 5.1 (610 glycans) depicted as relative 613 
fluorescence units (RFU). Screened sera were from cohorts with symptomatic 614 
hypogammaglobulinemia (HGG; n=76), specific antibody deficiency (SPAD; n=5), 615 
common variable immunodeficiency (CVID; n=25), CVID with low PPV vaccination 616 
response (CVID PPVlow; n=6), IgG subclass deficiency (IgGSD; n=8), or healthy 617 
donors (HD; n=43). Significant values are reported, Kruskal–Wallis test. (B) Glycan-618 
binding reactivity matrices for individual sera (HD: n=12; SPAD: n=5; IgGSD: n=8; 619 
HGG: n=11; CVID: n=12) screened on the NCFGv2 array and computed by the 620 
dendrogram clustering algorithm as outlined in Materials and Methods. The color key 621 
and distribution histogram are depicted. Columns represent the antibody reactivity 622 
profiles (reactivity of each specific glycan for the different sera samples), and the 623 
rows reflect the immune profiles for each patient subgroup, based on the mean 624 
relative fluorescent units (RFU) values. 625 
Figure 2. Recognition of bacterial carbohydrate epitopes in PADs. (A) 626 
Spearman’s rank correlation matrix for IgG recognition of pooled sera to all 121 627 
bacterial carbohydrate structures identified by BCSDB analysis on the CFG array. 628 
(B,C) Recognition of bacterial glycans by individual sera screened on the NCFGv2 629 
array. (B) Dendrogrammed reactivity matrix based on the mean RFU values for all 65 630 
glycans identified by BCSDB analysis. The color keys and distribution histograms are 631 
depicted. (C) Heatmap presentation of glycan-specific IgG binding to selected 632 
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epitopes from S. pneumoniae (n=2), H. influenzae (n=3), N. meningitidis (n=6), E. coli 633 
(n=15), H. pylori (n=15), and Salmonella (n=2) species. 634 
Figure 3. Recognition of tumor-associated carbohydrates (TACAs) by glycan-635 
specific IgG in PAD. (A, B) Recognition of TACAs by pooled serum IgG as 636 
screened on the CFG array and depicted as dendrogrammed glycan reactivity matrix 637 
based on ABR (A), or as radial dendrogram based on RFU values (B). (C) Heatmap 638 
presentation based on RFU values illustrating reactivity of individual serum IgG to 639 
TACAs as revealed by screening on the NCFGv2 array. The color keys and 640 
distribution histograms are depicted.  641 
Figure 4. Deviant recognition of distinct terminal carbohydrate moieties and 642 
specific loss of Gal reactivity in symptomatic PAD. (A) Binary deviation map (P 643 
< 0.05) of IgG immunoprofiles compared to healthy controls based on two-way 644 
ANOVA and hierarchical clustering analysis with identification of cliques 1-4. The 645 
rows in this matrix indicate the binary antibody reactivity profiles, and the columns 646 
represent the deviation immune profiles for each PAD subgroup. (B) Terminal 647 
carbohydrate moieties of epitopes in reactivity cliques 2 (non-significant deviation) 648 
and 4 (significant deviation). Numeric occurrence is indicated in parenthesis. (C, D) 649 
Recognition of Gal- (C) or GalNAc- (D) epitopes within clique 4 (significant 650 
deviation). (E) Deviation map based on degree of significance with identification of 651 
cliques A-E. (F) Bubble chart displaying terminal glycan structure distribution across 652 
cliques A-E. The size key and percentage numbers indicate frequencies. 653 
Figure 5. Diminished recognition of Gal-terminated glycan epitopes and 654 
reduced Gal-dependent xenogeneic anti-porcine reactivity of CVID and 655 
symptomatic IgGSD sera. (A) IgG antibody reactivity to Galili, LN and A3GN 656 
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glycans as assessed by suspension array (multiplex immunoassay). Individual sera 657 
from healthy donors (n=18), HGG patients (n=37), CVID (n=15) and IgGSD (n=8) 658 
patients were analyzed. Box-and-whisker diagrams were created by the Tukey 659 
method. The middle line is plotted at the median and the box represents the 660 
interquartile range (difference between the 25th and 75th percentiles). Significant 661 
values are reported, Kruskal–Wallis test. (B) Reduced surface staining of anti-Galili 662 
mAb reactivity following -galactosidase treatment of porcine PK15 cells, as 663 
assessed by flow cytometry. Representative histogram (left panel) and summary 664 
(right panel). (C) Antibody dependent cellular cytotoxicity (ADCC) activity of primary 665 
human NK cells against PK15 cells at E/T ratio of 10:1, in absence or presence of -666 
galactosidase. Significant values are reported (Student’s t-test). (D) Histopathologic 667 
analysis of pig skin damage in cryosections incubated with healthy and patient sera 668 
in presence of healthy human leukocytes. Representative examples for each 669 
analyzed disease and control (PBS) are shown (left panel). The dashed lines indicate 670 
the dermal-epidermal junction. Pictures were taken with 40X magnification, scale 671 
bars 75µm. The damage induced was calculated as the dermal-epidermal separation 672 
normalized to the IgG concentration in the sera (right panel) (at least n=7). Results 673 
are representative of at least three (C) or seven (D) experiments. Significant values 674 
are reported (Kruskal–Wallis test).  675 
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